SAN DIEGO, Feb. 19, 2019 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) – as well as European CE mark approval – for use of its Precice® Bone Transport …

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone